Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)

NCT04600895 is registered in ClinicalTrials.gov with Appili Therapeutics Inc. as lead sponsor.

NCT NCT04600895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04600895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)
Lead sponsor
Appili Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2020
Completion date
October 20, 2021
Enrollment
1,187 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

covid19